Dementia's New Puzzle: Abnormal Structure Spotted in Alzheimer's Brain Tissue
An international team affiliated with the University of Minnesota has published a study in Nature Neuroscience describing a never-before-described pathological feature: mitochondrial plaques (MPs) in the brains of both human patients and genetically modified mice. These plaques stem from defective mitophagy, the cellular mechanism that normally clears away damaged mitochondria, leaving them to pile up inside neurons. The discovery may help explain why removing amyloid plaques alone does not halt neurodegeneration, a critical concern in Alzheimer's care. It also adds a fresh angle to debates about why amyloid-focused therapies have failed to deliver consistent benefits.
Study Details and Outcomes
Released on August 3 at 15:30, the research provides new information about Alzheimer's, which affects approximately 57 million people around the world. The investigators detected mitochondrial plaques in brain tissue from patients as well as in genetically modified mice. For years, the main disease markers were thought to be beta-amyloid peptide deposits and pathological tau protein. The present study, however, shows that MPs form because of a failure in mitophagy, the process that disposes of damaged mitochondria.
Using Keima, a pH-sensitive fluorescent protein, the scientists identified the mitochondrial aggregates. These clumps arose independently and at the same time as amyloid plaques, then gradually merged with them. In the modified mice, MP accumulation began at 15 weeks of age, a stage that roughly matches early adulthood in humans. Importantly, healthy control brains showed no signs of MPs.
- Amyloid proteins build up outside cells, whereas MPs damage neurons from the inside.
- Lysosomes struggle to break down the damaged structures quickly enough.
- Clearing only amyloid plaques often does not stop neurodegeneration.
According to the researchers, future treatments will need to be dual-pronged: stimulate mitophagy and clear both toxic aggregate types from the brain. This advance could mark a significant step toward new Alzheimer's therapies and better patient outcomes.
The presence of mitochondrial plaques in Alzheimer's brains opens up new possibilities for understanding this intricate disease. Because conventional amyloid-targeted treatments have frequently fallen short of expectations, the latest findings may prompt more research in neurodegeneration. They likewise emphasize the need for an integrated treatment strategy that addresses the multiple pathological changes taking place in the brain.
In addition to mitochondrial plaques, recent studies have also highlighted the impact of excess weight on Alzheimer’s progression. Researchers have found a link between fat accumulation and brain function, suggesting that metabolic health may play a critical role in neurodegeneration. To explore this connection further, read about how weight may accelerate Alzheimer's disease.